# Motif Bio plc Presentation at BIO International Convention

- Link: https://www.directorstalkinterviews.com/motif-bio-plc-presentation-bio-international-convention/412730280
- Published: 2017-06-14T07:11:01+01:00
- Author: Giles Arbor

**Motif Bio plc** (LON:MTFB), the clinical stage biopharmaceutical company specialising
in developing novel antibiotics, announced today that the Company will present at
BIO 2017 being held at the San Diego Convention Center, 111 West Harbor Drive, San
Diego from 19-22 June 2017.

The presentation will provide information on the progress of its novel antibiotic
candidate, iclaprim, and will take place at 3.30pm on Wednesday, 21 June in Presentation
Theater 3. The presentation will be available shortly after on the company website:
www.motifbio.com

The BIO International Convention brings together over 16,000 biotechnology and pharma
leaders, covering a wide spectrum of life sciences areas including drug discovery,
biomanufacturing, genomics, biofuels, nanotechnology and cell therapy – for more
information see: http://convention.bio.org

Motif Bio Plc is a clinical-stage biopharmaceutical company, engaged in the research
and development of novel antibiotics designed to be effective against serious and
life-threatening infections in hospitalised patients caused by multi-drug resistant
bacteria. Our lead product candidate, iclaprim, is being developed for the treatment
of acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired
bacterial pneumonia (HABP), including ventilator associated bacterial pneumonia (
VABP), infections often caused by MRSA (methicillin resistant Staphylococcus aureus).
Having completed the REVIVE-1 trial, patients are currently being enrolled and dosed
in a second global Phase 3 clinical trial (REVIVE-2) with an intravenous formulation
of iclaprim, for the treatment of ABSSSI. Data readout for REVIVE-2 is expected 
in the second half of 2017.

Share on: